13F-HR filed by Decheng Capital LLC
Decheng Capital LLC filed this 13F-HR for the quarter ended 2024-12-31, filed 2025-02-14, with 28 holding rows worth $466,229,449.
- Accession
- 0001104659-25-013870
- Filer
- CIK 2010850
- Filed
- 2025-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2024
A holdings report, 28 entries on the cover page, a total value of $466,229,449 stated on the cover page (in dollars after the unit check, H1), rows summing to $466,229,449 with VALUE read as dollars as filed, 13F file number 028-23697. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 6,371,669 | $182,739,467 | dollars as filed | |
| NUVATION BIO INC COM CL A | 67080N101 | Stock | 25,954,439 | $69,038,808 | dollars as filed | |
| UPSTREAM BIO INC | 91678A107 | COMMON STOCK | 3,285,293 | $54,010,217 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 770,000 | $19,789,000 | dollars as filed | |
| ILLUMINA INC | 452327109 | COM | 94,767 | $12,663,715 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 808,789 | $12,042,868 | dollars as filed | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 76,772 | $12,027,102 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 226,000 | $9,885,240 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS | G4444C102 | COM | 171,600 | $9,292,140 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 167,958 | $8,587,693 | dollars as filed | |
| BEYONDSPRING INC | G10830100 | SHS | 4,882,651 | $7,958,721 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 189,098 | $7,951,571 | dollars as filed | |
| LYELL IMMUNOPHARMA INC | 55083R104 | COM | 11,909,341 | $7,621,978 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 2,338,095 | $7,084,428 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 84,377 | $6,470,872 | dollars as filed | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 694,254 | $5,637,342 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 2,266,667 | $5,621,334 | dollars as filed | |
| LEGEND BIOTECH CORP | 52490G102 | SPONSORED ADS | 153,558 | $4,996,777 | dollars as filed | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 100,000 | $4,704,000 | dollars as filed | |
| BIONTECH SE SPONSORED ADS | 09075V102 | ADR | 40,000 | $4,558,000 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 515,555 | $4,237,862 | dollars as filed | |
| EQUILLIUM INC | 29446K106 | COM | 4,447,308 | $3,327,476 | dollars as filed | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 400,000 | $2,228,000 | dollars as filed | |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 49,767 | $2,104,646 | dollars as filed | |
| ATRICURE INC | 04963C209 | COM | 26,797 | $818,916 | dollars as filed | |
| PYXIS ONCOLOGY INC COMMON STOCK | 747324101 | Stock | 326,810 | $509,824 | dollars as filed | |
| GRAIL INC | 384747101 | COM | 9,684 | $172,859 | dollars as filed | |
| NUVATION BIO INC | 67080N119 | WARR | 646,057 | $148,593 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-25-013870 | this filing | 2025-02-14 | acceptance time not in the bulk data set |